Novel 3D-printed device may offer a new method to test pharmaceuticals


Moving toward eliminating drug and chemical safety testing in animals

©filin174 –

Image credit: ©filin174 –

Researchers from the University of Edinburgh, Edinburgh, Scotland, will receive funding for the development of a device that they believe can replace the use of animals in the safety testing of drugs and chemicals. They are supported by Edinburgh Innovations, University’s commercialisation service.

According to a press release, this novel 3D printed device might replace the need for drug and chemical safety testing on animals.1 The researchers received £260,000 from the Medical Research Council to test the device using sterile materials. The device was proven to replicate drug perfusion, and the results were presented at the Microphysiological Systems World Summit in Germany in June 2023.

The plastic “body-on-chip” device, invented by Liam Carr, an in vitro pharmacology PhD student, mimics how a drug moves through the body’s organs. The movement is demonstrated using positron electron tomography (PET) imaging. The device currently includes five compartments that contain human cells representing the heart, lungs, kidney, liver and brain, connected by channels that mimic the human circulatory system, through which a small molecule drug is pumped.1

Other organs may be added such as the stomach or skin, in states representative of both human health and disease.

Regarding the eye, Adriana Tavares, BSc (Hons), MSc, PhD of the University’s Centre for Cardiovascular Science and supervisor of Mr Carr, said, “At the moment, we are unable to track drug movement in the eye, but the modular design of the chip could enable a reconfiguration of the compartments to enable drug kinetic analysis in compartments mimicking the eye.”

The potential use of the body-on-chip device so far shows potential even beyond drug development to the testing of aerosols, food and household products.

Regarding the performance of the device, Mr Carr commented, “Using mathematic modeling, we have found that the rate of transfer into the organ compartments and the uptake of nutrients in vitro mimics in vivo organ results. It’s been really exciting to be able to use PET imaging to modify the device and produce even flow through all organ compartments.”

Dr Tavares stated, “This device shows really strong potential to reduce the large number of animals that are used worldwide for testing drugs and other compounds, particularly in the early stages, where only 2% of compounds progress through the discovery pipeline.”

The importance of such a device is underscored by the fact that about 80,000 animals are used in early-stage drug development in Europe each year, without subsequent clinical benefit.

1. A novel 3D printed device that could replace the need for drug and chemical safety testing on animals has received new funding. News release. Edinburgh Innovations. Published November 28, 2023.

Related Videos
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
© 2024 MJH Life Sciences

All rights reserved.